Platelet-Activating Factor Antagonism: A New Concept in the Management of Regional Myocardial Ischemia-Reperfusion Injury

References

• Wilcox R G, Olsson C G, Skene A M, von der Lippe G, Jensen G, Hampton J R. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian study of early thrombolysis (ASSET). lancet. 1988; 2: 525–530
   PubMed Web of Science ®Google Scholar
• Gruppo ltaliano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397–401
   PubMedGoogle Scholar
• ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected myocardial infarction: ISIS-2. Lancet 1988; 2: 349–360
   PubMed Web of Science ®Google Scholar
• Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994; 343: 311–322
   PubMed Web of Science ®Google Scholar
• Kleiman N, Terrin M, Mueller H, Chaitman B, Roberts R, Braunwald E, Knatterud G, Solomon R, McMahan R, The TIMI investigators. Mechanisms of early death despite thrombolytic therapy: Experience from the Thrombolysis in Myocardial Infarction phase II (TIMI) study. J Am Coll Cardiol 1992; 19: 1129–1135
   PubMedGoogle Scholar
• Gotlieb A I, Havenith M G. Cardiovascular Pathology 2nd ed., M S Silver. Churchill Livingstone, New York 1991; 393–440
   Google Scholar
• Qayumi A K, Jamieson W RE. Pathophysiology of reperfusion injury in organ transplantation. Pathophysiology of Reperfusion Injury, D K Das. CRC Press, Boca Raton, FL 1993; 325–362
   Google Scholar
• Holland C E, Olson R E. Prevention by hypothermia of paradoxical calcium necrosis in cardiac muscle. J Mol Cell Cardiol. 1975; 7: 917–725
   PubMedGoogle Scholar
• Fleckenstein A, Lossnitzer K, Pfennigsdork G, Brauer H. Myocardium Vessels Calcium: An Illustrated Synopsis of the Principle of Calcium Antagonism. Ag Knoll, Ludwigshafen, Munich 1983
   Google Scholar
• Free Radical Reactions in Medicine, J Feher, G Cosmos, A Vereckei. Springer-Verlag, Berlin 1987; 24–56
   Google Scholar
• McCord J M, Fridovich I. Superoxide dismutases: A history. Superoxide and Superoxide Dismutases, A M Michelson, J M McCord, I Fridovich. Academic Press, San Francisco 1977; 1–17
   Google Scholar
• Physiology of Oxygen Radicals, A E Taylor, S Matalon, P A Ward. USA Waverly Press, San Francisco 1986; 120–133
   Google Scholar
• Hearse D J, Manning A S, Downey J M, Yellon D M. Xanthine oxidase: A critical mediator of myocardial injury during ischemia and reperfusion. Acta Physiol Scand. 1986; 548(suppl)65–78
   Google Scholar
• Kozlov A V, Shinkarenko L I, Vladimirov I UA, Aziozova O A. The role of endogenous free iron in activating lipid peroxidation in ischemia. Biull Eksp Biol I Med. 1985; 99: 65–78
   Google Scholar
• Meerson R Z, Kagan V E, Lozlov Y P, Belkina L M, Arkhipenko Y V. The role of lipid peroxidation in pathogenesis of ischemic damage and antioxidant protection of the heart. Basic Res Cardiol. 1982; 77: 465–485
   PubMed Web of Science ®Google Scholar
• Torok B, Roth E, Zsoldos T, Tigyi A, Matkovics B, Szabo L. Lipid peroxidation in lung of rats exposed to hyperoxic, hypoxic and ischemic effects. Exp Pathol. 1986; 29: 221–226
   PubMedGoogle Scholar
• White B C, Krause G S, Aust D D, Eyster G E. Postischemic tissue injury by iron-mediated free radical lipid peroxidation. Ann Emerg Med. 1985; 14: 804–809
   PubMed Web of Science ®Google Scholar
• Pober J S, Cotran R S. The role of endothelial cell in inflammation. Transplant 1990; 50: 537–544
   PubMed Web of Science ®Google Scholar
• Brenner B M, Troy J L, Blatermann B J. Endothelium-dependent vascular responses. Mediators and mechanisms. J Clin Invest. 1989; 84: 1373–1378
   PubMed Web of Science ®Google Scholar
• Camussi G, Brentjens J R. Platelet-Activating Factor and Related Lipid Mediators, F Snyder. Plenum Press, New York 1987; 299
   Google Scholar
• Ontell S J, Makowka L, Boccagni P, Starzl T E. The role of PAF and its antagonism in transplantation: Organ ischemia and preservation. Platelet Activating Factor in Endotoxin and immune Diseases, D A Handley, R N Saunders, W J Houlihan, J C Tomesch. Marcel Dekker, New York 1990; 419
   Google Scholar
• Tsujimoto M, Toyama Y, Baer E, Stanacev N Z. Phosphonolipids. II: Synthesis of dialkyl L-alpha-glyceryl-(c-2 aminoethyl) phosphonates. J Biol Chem. 1965; 240: 44–48
   PubMedGoogle Scholar
• Carter H E, Smith D B, Jones D N. A new ethanolamine-containing lipide from egg yolk. J Biol Chem. 1958; 232: 681–694
   PubMedGoogle Scholar
• Renkonen O. Lecithins of glycerol ether character in normal human serum. Biochim Biophys Acta. 1962; 59: 497–499
   PubMedGoogle Scholar
• Pietruzko R, Gray R E. The products of mild alkaline and mild acid hydrolysis of plasmalogens. Biochim Biophys Acta. 1962; 56: 232–239
   PubMedGoogle Scholar
• Muirhead E E, Rightsel W A, Leach B E, Byers L W, Pitcock V A, Brooks B. Reversal of hypertension by transplants and extracts of cultured renomedullary interstitial cells. Lab invest. 1977; 35: 162–172
   Google Scholar
• Benveniste J, Henson P M, Cochrane C G. Leukocyte-dependent histamine release from rabbit platelets: The role of IgE, basophils, and a platelet-activating factor. J Exp Med. 1972; 136: 1356–1377
   PubMed Web of Science ®Google Scholar
• Benveniste J, Tence M, Varenne P, Bidault J, Boullet C, Polonsky J. Semi-synthesis and proposed structure of platelet-activating factor (PAF): PAF-acether an alkyl ether analog of lysophosphatidylcholine. CRC Acad Sci. 1979; 289D: 1937–2040
   Google Scholar
• Blank M L, Snyder F, Byers L W, Brooks B, Muirhead E E. Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. Biochem Biophys ReS Commun. 1979; 90: 1194–1200
   PubMed Web of Science ®Google Scholar
• Demopoulos C A, Pinckard R N, Hanahan D J. Platelet-activating factor. Evidence for 1-O-alkyl-2–acetyl-sn-glyceryl-3-phosphorylcholine as the active component (as a new class of lipid chemical mediators). J Biol Chem. 1979; 254: 9355–9358
   PubMed Web of Science ®Google Scholar
• Polonsky J, Tence M, Varenne P, Das B P, Lunel J, Benveniste J. Release of 1-O-alkylglyceryl-3-phosphorylcholine, O-deacetyl platelet-activating factor, from leukocytes: Chemical ionization mass spectrometry of phospholipids. Proc Natl Acad Sci U S A 1980; 77: 7019–7023
   PubMed Web of Science ®Google Scholar
• Rabinovici R, Yue T-L, Feuerstein G. Platelet-activating factor in cardiovascular stress situations. Lipids. 1991; 26: 1257–63
   PubMedGoogle Scholar
• Snyder F. Chemical and biochemical aspects of platelet activating factor: A novel class of acetylated ether-linked choline phospholipids. Med Res Rev. 1985; 5: 107–140
   PubMed Web of Science ®Google Scholar
• Summers J B, Albert A H. Platelet activating factor antagonists. Adv Pharm. 1995; 32: 67–168
   PubMedGoogle Scholar
• Braquet P, Touqui L, Shen T Y, Vargaftig B B. Perspectives in platelet-activating factor research. Pharmacol Rev. 1987; 39: 97–145
   PubMed Web of Science ®Google Scholar
• Snyder F, Lee T-C, Blank M L. The role of transacylases in the metabolism of arachidonate and platelet-activating factor. Prog Lipid Res. 1992; 31: 65–86
   PubMedGoogle Scholar
• Winkler J D, Chilton F H. The role of CoA-independent transacylases in the production of platelet-activating factor and the metabolism of arachidonate. Drug News Perspec. 1993; 6: 133–138
   Google Scholar
• Wykle R L, Malone B, Snyder F. Enzymatic synthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine, a hypotensive and platelet-aggregating lipid. J Biol Chem. 1980; 255: 10256–10260
   PubMed Web of Science ®Google Scholar
• Woodard D S, Lee T-L, Snyder F. The final step in the de novo biosynthesis of platelet activating factor. J Biol Chem. 1987; 262: 2520–2527
   PubMedGoogle Scholar
• Lee T-L, Malone B, Snyder F. Formation of 1-alkyl-2-acetyl-sn-glycerols via the de novo biosynthetic pathway for platelet-activating factor. J Biol Chem. 1988; 263: 1755–1760
   PubMedGoogle Scholar
• Snyder F. Enzymatic pathways for platelet-activating factor, related alkyl glycerolipids and their precursors. Platelet-Activating Factor and Related Lipid Mediators, F Snyder. Plenum, New York 1987
   Google Scholar
• Smiley P L, Stremler K E, Prescott S M, Zimmerman G A, McIntyre T M. Oxidatively fragmented phosphatidylcholines activate human neutrophils through the receptor for platelet-activating factor. J Biol Chem. 1991; 266: 11104–11110
   PubMed Web of Science ®Google Scholar
• Tanaka T, Iimori M, Tsukatani H, Tokumura A. Platelet-aggregating effects of platelet-activating factor like phospholipids formed by oxidation of phosphatidylcholines containing an sn-2-polyunsaturated fatty acyl group. Biochim Biophys Acta. 1994; 1210: 202–208
   PubMedGoogle Scholar
• Lynch M J, Grum C M, Gallagher K P, Bolling S F, Deeb G M, Morganroth M L. Xanthine oxidase inhibition attenuates ischemic reperfusion injury. J Surg Res 1988; 44: 538–544
   PubMed Web of Science ®Google Scholar
• Stewart A G, Dubbin P N, Harris T, Dusting G J. Evidence for an intracellular action of PAF in bovine cultured aortic endothelial cells. Br J Pharmacol. 1989; 96: 503–505
   PubMedGoogle Scholar
• Albert D H, Snyder F. Biosynthesis of 1-alkyl-2 acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) from 1-aIkyl-2-acyl-sn-glycero-3-phosphochoIine by rat alveolar macrophages. J Biol Chem. 1983; 258: 97–102
   PubMed Web of Science ®Google Scholar
• Pieroni G, Hanahan D J. Metabolic behavior of acetyl glyceryl ether phosphorylcholine on interaction with rabbit platelets. Arch Biochem Biophys. 1983; 224: 485–493
   PubMedGoogle Scholar
• Blank M L, Lee T-C, Fitzgerald V, Snyder F. A specific hydrolase for 1 -alkyl-2-acetyl-sn-glycero-3-phosphocholine hypotensive platelet activating lipid. J Biol Chem. 1981; 256: 175–178
   PubMed Web of Science ®Google Scholar
• Kleiman N S, White H D, Ohman E M, Ross A M, Woodlief L H, Califf R M, Holmes D R, Bates E, Pfisterer M, Vahanian A, Topol E J. Mortality within 24 hours of thrombolysis for myocardial infarction: The importance of early reperfusion. Circulation 1994; 90: 2658–2665
   PubMedGoogle Scholar
• Kim Y D, Danchak R M, Heim K F, Lees D E, Myers A K. Constriction of canine coronary arteries by platelet activating factor after brief ischemia. Prostaglandins 1993; 46: 269–276
   PubMed Web of Science ®Google Scholar
• Abraham E, Schoemaker W C, Bland R D, Cobo J C. Sequential cardiorespiratory patterns in septic shock. Crit Care Med. 1983; 11: 799–803
   PubMedGoogle Scholar
• Harlan J M, Winn R K. The role of phospholipase products in the pathogenesis of vascular injury in sepsis. Septic Shock? Newer Concepts in the Pathophysiology and Treatment, M Sande, R R Root. Churchill Livingstone, New York 1988; 83–104
   Google Scholar
• Parker C W. Systemic Anaphylaxis. Clinical Immunology, C W Parker. WB Saunders, Philadelphia 1980; 1208–1218
   Google Scholar
• Smith P L, Kagey-Sobotka A, Bleecker E R, Traystman R, Kaplan A P, Gralnick H, Valentine M D, Permutt S, Lichtenstein L M. Physiologic manifestation of human anaphylaxis. J Clin Invest. 1980; 66: 1072–1080
   PubMed Web of Science ®Google Scholar
• Bleecker E R, Lichtenstein L M. Current Therapy in Allergy and Immunology, L M Lichtenstein, A S Fauci. C. V. Mosby, St Louis 1983; 78–83
   Google Scholar
• Laurindo F R, Goldstein R E, Davenport N J, Ezra D, Feuerstein G Z. Mechanisms of hypotension produced by platelet-activating factor. J Appl Physiol. 1989; 66: 2681–2690
   PubMedGoogle Scholar
• Flores N A, Sheridan D J. Electrophysiological and arrhythmogenic effects of platelet activating factor during normal perfusion, myocardial ischaemia and reperfusion in the guinea-pig. Br J Pharmacol 1990; 101: 734–738
   PubMedGoogle Scholar
• Chakrabarty S, Thomas P, Sheridan D J. Contribution of platelets and platelet-activating factor (PAF) to the arrhythmogenic, haernodynamic and necrotic effects of acute myocardial ischaemia. Eur Heart J. 1991; 12: 583–589
   PubMedGoogle Scholar
• Felix S B, Baumann G, Ahmad Z, Hashemi T, Niemczyk M, Berdel W E. Effects of platelet-activating factor on myocardial contraction and myocardial relaxation of isolated perfused guinea pig hearts. J Cardiovasc Pharmacol. 1990; 16: 750–756
   PubMedGoogle Scholar
• Stahl G L, Lefer D J, Lefer A M. PAF-acether induced cardiac dysfunction in the isolated perfused guinea pig heart. Naunyn-Schmiedeberg's Arch Pharmacol. 1987; 336: 459–463
   Google Scholar
• Sawa Y, Schaper J, Roth M, Nagasawa K, Ballagi G, Bleese N, Schaper W. Platelet-activating factor plays an important role in reperfusion injury in myocardium. J Thorac Cardiovasc Surg. 1994; 108: 953–959
   PubMedGoogle Scholar
• Qayumi A K, English J C, Godin D V, Ansley D M, Loucks E B, Lee J U, Kim C W. The role of platelet activating factor in the pathophysiology of regional myocardial ischemia-reperfusion injury. Ann Thorac Surg, In press
   Google Scholar
• Ko W, Lang D, Hawes A S, Zelano J A, Isom O W, Krieger K. Platelet-activating factor antagonism attenuates platelet and neutrophil activation and reduces myocardial injury during coronary reperfusion. J Surg Res. 1993; 55: 504–515
   PubMed Web of Science ®Google Scholar
• Qayumi A K, Godin D V, English J C, Loucks E B, Lim S PAl, Mahmeed T, Horley K J, Gul S. Therapeutic potential of PAF antagonist in the management of myocardial infarction. Ann ThorSurg, Submitted
   Google Scholar
• Katoh S, Toyama J, Kodama I, Koike A, Toshio A. Role of platelet activating factor in ischaemia-reperfusion injury of isolated rabbit hearts: Protective effect of a specific platelet activating factor antagonist, TCV-309. Cardiovasc Res. 1993; 27: 1430–1434
   PubMedGoogle Scholar
• Vleeming W, Werner J, Porsius A J. Modulation of antigen- and ischemia-induced effects by the platelet-activating factor antagonist WEB-2086 in isolated sensitized rat hearts. J Cardiovasc Pharmacol. 1992; 20: 790–799
   PubMedGoogle Scholar
• Koltai M, Tosaki A, Hosford D, Braquet P. Ginkolide B protects isolated hearts against arrhythmias induced by ischemia but not reperfusion. Eur l Pharmacol. 1989; 164: 293–302
   PubMedGoogle Scholar
• Koltai M, Tosaki A, Hosford D, Esanu A, Braquet P. Effect of BN 50639, a new platelet activating factor antagonist, on ischaemia induced ventricular arrhythmias in isolated working rat hearts. Cardiovasc Res. 1991; 25: 391–397
   PubMedGoogle Scholar
• Robertson D A, Genovese A, Levi R. Negative inotropic effect of platelet-activating factor on human myocardium: A pharmacological study. J Pharmacol Exp Ther 1987; 243: 834–839
   PubMedGoogle Scholar
• Camussi G, Alloatti G, Montrucchio G, Meda M, Emanuelli G. Effect of platelet activating factor on guinea-pig papillary muscle. Experientia. 1984; 40: 697–699
   PubMedGoogle Scholar
• Robertson D A, Wang D-Y, Lee C O, Levi R. Negative inotropic effect of platelet-activating factor: Association with a decrease in intracellular sodium activity. J Pharmacol Exper Ther 1988; 245: 124–128
   PubMedGoogle Scholar
• Delbridge L M, Stewart A G, Goulter C M, Morgan T O, Harris P J. Platelet-activating factor and WEB-2086 directly modulate rat cardiomyocyte contractility. J Mol Cell Cardiol. 1994; 26: 185–193
   PubMedGoogle Scholar
• Janero D R, Burghardt C. Production and release of platelet-activating factor by the injured heart-muscle cell (cardiomyocyte). Res Commun Chem Pathol Pharmacol 1990; 60: 201–218
   Google Scholar
• Sugimoto T, Tsuchimochi H H, McGregor C GA, Mutoh H, Shimizu T, Kurachi Y. Molecular cloning and characterization of the platelet-activating factor receptor gene expressed in the human heart. Biochem Biophys Res Commun. 1992; 189: 617–624
   PubMedGoogle Scholar
• Schwinger R HG, Bohm M, Rosee K L, Erdmann E. Existence of PAF receptors in human platelets and human lung tissue but not in the human myocardium. Am Heart J. 1992; 124: 320–330
   PubMedGoogle Scholar
• Piper P J, Stewart A G. Coronary vasoconstriction in the rat, isolated perfused heart induced by platelet-activating factor is mediated by leukotriene C4. Br J Pharmacol. 1986; 88: 595–605
   PubMedGoogle Scholar
• Piper P J, Stewart A G. Antagonism of vasoconstriction induced by platelet-activating factor in guinea-pig perfused hearts by selective platelet-activating factor receptor antagonists. Br J Pharmacol. 1987; 90: 771–783
   PubMedGoogle Scholar
• Hu W, Man R YK. Interaction of vasoactive substances released by platelet-activating factor in the rat perfused heart. Br J Pharmacol. 1991; 104: 933–937
   PubMed Web of Science ®Google Scholar
• Benveniste J, Boullet C, Brink C, Labat C. The actions of PAF-acether (platelet-activating factor) on guinea pig isolated heart preparations. Br J Pharmacol. 1983; 80: 81–83
   PubMedGoogle Scholar
• Saeke S, Masugi F, Ogihara T, Otsuka A, Kumahara Y, Watanabe K, Tarnure K, Akashi A, Kumagai A. Effects of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) on cardiac function in perfused guinea-pig heart. Life Sci. 1985; 37: 325–329
   PubMedGoogle Scholar
• Feuerstein G Z, Boyd L, Ezra D, Goldstein R. Effect of platelet activating factor on the coronary circulation of the domestic pig. J Am Physiol. 1984; 246: H466–H471
   Google Scholar
• Vleeming W, Wemer J, Porsius A J. Modulation of antigen- and ischemia-induced effects by the platelet-activating factor antagonist WEB-2086 in isolated sensitized rat hearts. J Cardiovasc Pharmacol. 1992; 20: 790–799
   PubMedGoogle Scholar
• Bussolino F, Camussi G. Platelet activating factor produced by endothelial cells: A molecule with autocrine and paracrine properties. Eur J Biochem. 1995; 229: 327–337
   PubMedGoogle Scholar
• Camussi G, Tetta C, Bussolino F, Baflioni C. Synthesis and release of platelet activating factor is inhibited by plasma a1 antichymotripsin and is stimulated by proteinases. J Exp Med. 1988; 168: 1293–1316
   PubMed Web of Science ®Google Scholar
• Sun D X, Rui Y C, Zeng G Q, Zhu J, Shen Y A. Specific binding sites of platelet activating factor in the intact bovine cerebral microvascular endothelial cells and antagonism of drugs. Acta Pharm Sinica. 1992; 57: 326–329
   Google Scholar
• Korth R, Hirafuji M, Keraly C L, Delatuer D, Bidault J, Benveniste J. Interaction of antagonist WEB 2086 and its hetrazepine analogue with human platelets and endothelial cells. Biochem Pharmacol. 1989; 44: 223–229
   Google Scholar
• Wainwright C L, Parratt J R, Bigaud M. The effects of PAF antagonists on ischaemia and reperfusion arrhythmias and ischemia-induced platelet aggregation. Biomed Biochim Acta 1988; 10/11: S224–S227
   Google Scholar
• Auchampach J A, Maruyama M, Cavero I, Gross G J. Blocking platelet activating factor receptors with RP 59227 decreases myocardial infarct size and the incidence of ventricular fibrillation. J Mol Cell Cardiol. 1991; 23: 552
   Google Scholar
• Chakrabarty S, Thomas P, Sheridan D J. Contribution of platelets and platelet-activating factor (PAF) to the arrhythmogenic, haemodynamic and necrotic effects of acute myocardial ischaemia. Eur Heart J. 1991; 12: 583–589
   PubMedGoogle Scholar
• Montrucchio G, Alloatti G, Mariano F, De Paulis R, Comino A, Emanuelli G, Camussi G. Role of platelet-activating factor in the reperfusion injury of rabbit ischemic heart. Am J Pathol. 1990; 137: 71–83
   PubMedGoogle Scholar
• Wainwright C L, Parratt J R, Bigaud M. The effects of PAF antagonists on arrhythmias and platelets during acute myocardial ischaemia and reperfusion. Eur Heart J. 1989; 10: 235–243
   PubMed Web of Science ®Google Scholar
• Leong L L, Sturm M J, Papadimitriou J M, Stephens C J. The effects of a PAF antagonist on ischemic myocardial damage and arrhythmia in the dog. J Mol Cell Cardiol. 1992; 24: 641–649
   PubMedGoogle Scholar
• Black S C, Driscoll E M, Lucchesi B R. Inhibition of platelet-activating factor fails to limit ischemia and reperfusion-induced myocardial damage. J Cardiovasc Pharmacol. 1992; 20: 997–1005
   PubMed Web of Science ®Google Scholar
• Ma X-L, Weyrich A S, Krantz S, Lefer A. Mechanisms of the cardioprotective actions of WEB-2170, bepafant, a platelet activating factor antagonist, in myocardial ischemia and reperfusion. J Pharmacol Exp Ther. 1992; 260: 1229–1236
   PubMedGoogle Scholar
• Stewart A G, Dusting G J. Characterization of receptors for platelet-activating factor on platelets, polymorphonuclear leukocytes and macrophages. Br J Pharmacol. 1988; 94: 1225–1233
   PubMedGoogle Scholar
• Marcheselli V L, Rossowska M J, Domingo M T, Braquet P, Bazan N G. Distinct platelet-activating factor binding sites in synaptic endings and in intracellular membranes of rat cerebral cortex. J Biol Chem. 1990; 265: 9140–9145
   PubMed Web of Science ®Google Scholar
• Houlihan W J. Platelet-activating factor antagonists. Platelet-Activating Factor in Endotoxin and Immune Diseases, D A Handley, R N Saunders, W J Houlihan, J C Tomesch. Marcel Dekker, New York 1990; 31–76
   Google Scholar
• Terashita Z, Tsushima S, Yoshioka Y, Nomura H, Inada Y, Nishikawa K. CV-3988. A specific antagonist of platelet-activating factor (PAF). Life Sci. 1983; 32: 1975–1982
   PubMed Web of Science ®Google Scholar
• Terashita Z, Imura Y, Nishikawa K. Inhibition by CV-3988 of the binding of [3H]-platelet activating factor (PAF) to the platelet. Biochem Pharmacol. 1985; 34: 1491–1495
   PubMed Web of Science ®Google Scholar
• Robertson D N, Smith G M. CV-3988 inhibits in vivo platelet aggregation induced by PAF-acether and collagen. Eur J Pharmacol 1986; 123: 91–97
   PubMedGoogle Scholar
• Nunez D, Chignard M, Korth R, Le Couedic J P, Norel X, Spinnewyn B, Braquet P, Benveniste J. Specific inhibition of PAF-acether induced platelet activating by BN 502021 and comparison with the PAF-acether inhibitors kadsure-none and CV-3988. Eur J Pharmacol. 1986; 123: 197–205
   PubMedGoogle Scholar
• Oura Y, Sakiyama N, Ueshima R, Higuchi M, Kakishita E, Nagai K. Effect of platelet activating factor on the collagen-induced platelet aggregation in whole blood. Thromb Haemost. 1987; 58: 185
   Google Scholar
• Terashita Z, Imura Y, Shino A, Nishikawa K. A lethal role of platelet activating factor in anaphylactic shock in mice. J Pharmacol Exp Ther. 1987; 243: 378–383
   PubMed Web of Science ®Google Scholar
• Toth P D, Mikulaschek A W. Effects of a platelet-activating factor antagonist, CV-3988 on different shock models in the rat. Circ Shock. 1986; 20: 193–203
   PubMedGoogle Scholar
• Wallace J L, Steel G, Whittle B J. Gastrointestinal plasma leakage in endotoxic shock. Inhibition by prostaglandin E2 and a platelet-activating antagonist. Can J Physiol Pharmacol. 1987; 65: 1428–1432
   PubMedGoogle Scholar
• Satoh H, Adachi M, Imai T, Okazawa A, Kamiya T, Nishikata N, Kobayashi H, Takahashi T, Yamaguchi H. The effects of specific antagonist of PAF (CV-3988) on airway hyperresponsiveness induced by ozone exposure in beagles. Aerugi. 1987; 36: 306–312
   PubMedGoogle Scholar
• Lang M, Hansen D, Hahn H L. Effects of PAF-antagonist CV-3988 on PAF-induced changes in mucous secretions and in the respiratory and circulatory variables in ferrets. Agents Actions 1987; 21(suppl)245–252
   PubMedGoogle Scholar
• Arnout J, van Hecken A, Depeleire I, Miyamoto Y, Holmes I, Deschepper P, Vermylen J. Effectiveness and tolerability of CV-3988, a selective PAF antagonist, after intravenous administration to man. Br J Clin Pharmacol. 1988; 25: 445–451
   PubMed Web of Science ®Google Scholar
• Takatani M, Maezaki N, Imura Y, Terashita Z-I, Nishikawa K, Tsushima S. Platelet activating (PAF) antagonists; Development of a highly potent PAF antagonist, TCV-309. Advances in Prostaglandin, Thromboxane and Leukotriene Research, B Samuelsson. Raven Press, New York 1990; 943–946
   Google Scholar
• Terashita Z-I, Imura Y, Takatani M, Tsushima S, Nishikawa K. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo. J Pharmacol Exp Ther. 1987; 242: 263–268
   PubMed Web of Science ®Google Scholar
• Terashita Z-I, Takatani M, Nishikawa K. Pharmacological profile of TCV-309:A potent PAF antagonist. J Lipid Mediat. 1992; 5: 83–185
   Google Scholar
• Terashita Z-I, Kawamura M, Takatani M, Tsushima S, Imura Y, Nishikawa K. The beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents. J Pharmacol Exp Ther. 1992; 260: 748–755
   PubMed Web of Science ®Google Scholar
• Prous J, Mealy N, Castaner J. TCV-309. Drugs Fut. 1993; 18: 721–725
   Google Scholar
• Handley D A. Development and therapeutic indications for PAF antagonists. Drugs Fut. 1988; 13: 137–152
   Google Scholar
• Shen T Y, Yang S S, Hwang S-B. Indene derivatives useful as PAF-antagonists. Eur Pat Appl 1985; 142: 801, (May 29)
   Google Scholar
• Hwang S-B, Chang M N, Garcia M L, Han Q Q, Huang L, King V F. L-652,469—a dual receptor antagonist of platelet activating factor and dihydropyridines from Tussilago farfara L. Eur J Pharmacol. 1987; 141: 269–281
   PubMedGoogle Scholar
• Shen T Y, Hwang S-B, Chang M N, Doebber T W, Lam M-H, Wu M S, Wang X, Han G Q, Li R Z. Characterization of a platelet-activating factor receptor antagonist isolated from heifenteng (piper futokadsurae): Specific inhibition in vitro and in vivo platelet-activating factor-induced effects. Proc Natl Acad Sci USA 1985; 82: 672–676
   PubMedGoogle Scholar
• Shen T Y, Hussaini I M. Kadsurenone and other related lignans as antagonists of PAF receptor. Methods in Enzymology, R C Murphy, F A Fitzpatrick. Academic Press, San Diego 1990; 446–454
   Google Scholar
• Braquet P, Braquet P, Toqui L, Shen T Y, Vargaftig B B. Perspectives in platelet-activating factor research. Pharmacol Rev 1987; 39: 97–145
   PubMed Web of Science ®Google Scholar
• Okamoto M, Yoshida K, Uchida I, Nishikawa M, Koshaka M, Aoki H. Studies on platelet activating factor (PAF) antagonists from microbial products: I. Bis-dethiobis-(methylthio)gliotoxin and its derivatives. Chem Pharm Bull. 1986; 34: 340–344
   PubMed Web of Science ®Google Scholar
• Kirby G W, Robins D J, Sefton M A, Talekar R R. Biosynthesis of bisbethiobis(methylthio)gliotoxin, a new metabolite of Gliocladium deliquescens. J Chem Soc Perkins Trans. 1980; 1: 119
   Google Scholar
• Casals-Stenzel J, Weber K H. Triazolobenzodiazepines: Dissociation of their PAF (platelet activating factor) antagonists and CNS activity. J Pharmacol. 1987; 90: 139–146
   Google Scholar
• Casals-Stenzel J, Muacevic G, Weber K-H. Pharmacological actions of WEB-2086, a new specific antagonist of platelet activating factor. J Pharmacol Exp Ther. 1987; 241: 974–981
   PubMed Web of Science ®Google Scholar
• Casals-Stenzel J, Weber K H. Triazoloidiazepines: disassociation of their PAF (platelet-activating factor) antagonistic and CNS activity. Brit J Pharmacol. 1987; 90: 139–146
   PubMedGoogle Scholar
• Heuer H, Casals-Stenzel J, Muacevic G, Stransky W, Weber K-H. Effect of the PAF-antagonists WEB 2170 and STY 2108, two hetrazepines with PAF-antagonistic activity on PAF-induced changes in vitro and in vivo. Recent Advances in Platelet-Activating Factor. BrisbaneAustralia September 3–5, 1987, abstract 4
   Google Scholar
• Braquet P. Treatment or prevention of PAF-acether disorders provoked by a new series of highly specific inhibitors. Brit. Pat. 8418424, July 19, 1984, Belg Pat. 901,915; see Chem Abstr. 1985;103:189808d
   Google Scholar
• Braquet P, Drieu P, Etienne A. Le Ginkgolide B (BN 52021): Un puissant inhibiteur du PAF-acether isole du Ginkgo biloba L. Actual Chim Ther (Paris). 1985; 13: 237–254
   Google Scholar
• Dupont L, Germain G, Dideberg O. Crystal and molecular structure of BN 52021, a PAF-acether antagonist, compared with the conformation of kadsurenone and related compounds. Pharmacol Res Commun. 1986; 18: 25–32
   PubMedGoogle Scholar
• Dupont L, Dideberg O, Germain G, Braquet P. Structure of ginkgolide B (BN 52021) monohydrate: C20H24O11*H2O, a highly specific PAF-acether receptor antagonist isolated from Ginkgo biloba L. Acta Cristallogr 1986; C42: 1759–1762
   Google Scholar
• Desquand S, Touvay C, Tandon J, Lagente V, Maridonneau-Parini I, Lefort J, Etienne A, Braquet P, Vergaftig B B. Interference of Ginkgolide B (BN 52021) with the bronchopulmonary effects of PAF-acether in the guinea pig. Eur J Pharmacol. 1986; 127: 83–95
   PubMed Web of Science ®Google Scholar
• Sanchez-Crespo M, Fernandez-Gallardo S, Nieto M L, Barones J, Braquet P. Inhibition of the vascular action of IgG aggregates by BN 52021, a highly specific antagonist of PAF-acether. Immunopharmacology 1985; 10: 69–75
   PubMedGoogle Scholar
• Weber K H, Heuer H, Birke F, Bechtel W, Harreus A, Stransky W, Walther G, Casals-Stenzel J. 2, 2-Annelated thienotriazolo-1,4-diazepines as PAF antagonists (and its structure-activity relationship). Recent Advances in Platelet Activating Factor. BrisbaneAustralia 1987, September 3–5, abstract 15
   Google Scholar
• Wallace J L, Steel G, Whittle B JR, Lagente V, Vargaftig B B. Evidence for platelet activating factor (PAF) as a mediator of endotoxin-induced gastrointestinal damage in the rat: Effects of three PAF antagonists. Gastroenterology 1987; 93: 765–773
   PubMed Web of Science ®Google Scholar
• Droy-Lefaix M T, Drouet Y, Geraud G, Braquet P. The amplicative role of PAF-acether in the oxidative stress following the reperfusion of ischemic stomach. Bas Life Sci. 1988; 49: 887–890
   PubMedGoogle Scholar
• Verbey N U, van Delft J, Oosterhuis J A, Braquet P, van Haeringen N J. Interference of a PAF-acether antagonist, BN-52021, in corneal and iris models of eye disease. Recent Advances in Platelet Activating Factor. BrisbaneAustralia 1987, September 3–5, abstract 6
   Google Scholar
• Touvay C, Vilain B, Menica-Huerta J M, Braquet P. Endotoxin-induced inhibition of beta-adrenergic relaxation in guinea-pig lung: Effects of BN 52021. Recent Advances in Platelet Activating Factor. BrisbaneAustralia September 3–5, 1987, abstract 27
   Google Scholar
• Adnot S, Lefort J, Lagente V, Braquet P, Vargaftig B B. Interference of BN 52021, a PAF-acether antagonist, with endotoxin induced hypotension in the guinea pig. Pharmacol Res Commun. 1986; 18: 197–200
   PubMedGoogle Scholar
• Adnot S, Lefort J, Braquet P, Vargaftig B B. Interference of the PAF-acether antagonist BN 52021 with endotoxin-induced hypotension in the guinea pig. Prostaglandins 1986; 32: 791–802
   PubMedGoogle Scholar
• Etienne A, Hecquet F, Soulard C, Spinnewyn B, Clostre F, Braquet P. In vivo inhibition of protein leakage and Salmonella enteritidis-induced mortality in the rat by a specific PAF-acether antagonist: BN 52021. Agents Actions 1985; 17: 368–370
   Google Scholar
• Trebieb H A, Calixto J B. Further evidences for the mechanism involved in Bothrops jararaca venom-induced oedema in the rat paw. Franco Brazilian Symposium on Chemistry and Pharmacology of Natural Products in Inflammation Allergy and Thrombosis, Rio de Janeiro. November 16–19, 1986
   Google Scholar
• Lopez-Farre A, Gomez-Garre D, Bernabeu F, Ramon Y, Cajal S, Lopez-Novoa J M. Platelet-activating factor mediates glycerol-induced acute renal failure in rats. Clin Sci. 1990; 79: 551–558
   Web of Science ®Google Scholar
• Lagente V, Touvay C, Randon J, Desquand S, Cirino M, Villain B. Interference of the PAF-acether antagonist BN 52021 with passive anaphylaxis in the guinea pig. Prostaglandins 1987; 33: 256–274
   Google Scholar
• Braquet P, Etienne A, Touvay C, Bourgain R H, Lefort J, Vargaftig B B. involvement of platelet activating factor in respiratory anaphylaxis, demonstrated by PAF-acether inhibitor BN 52021 (letter). Lancet. 1985; 1: 1501
   PubMedGoogle Scholar
• Lellouch-Tubiana A, Lefort J, Simon M-T, Pfister A, DaLage C, Vargaftig B B. Comparison of the eosinophilotactic effect of PAF-acether and antigen in vivo: The role of PAF-acether antagonists and platelets. The Role of Platelet Activating Factor in the Immune Response. Paris June 25–26, 1987, 41 (Abst.)
   Google Scholar
• Coyle A J, Robertson D N, Page C P. The role of PAF in antigen-induced eosinophil accumulation in the lung. The Role of Platelet Activating Factor in the Immune Response. Paris June 25–26, 1987, 42 (Abst.)
   Google Scholar
• Koltai M, Lepran I, Szekeres L, Viossat I, Chabrier P E, Braquet P. Effect of BN 52021, a specific PAF-acether antagonist, on cardiac anaphylaxis in Langendorff hearts isolated from passively sensitized guinea pigs. Eur J Pharmacol. 1986; 130: 133–136
   PubMed Web of Science ®Google Scholar
• Foegh M L, Bijan S, Khirbadi B S, Rowles J R, Ramwell P W. Synergistic effect of a PAF antagonist with azathioprine and cyctosprin in allograft survival. New Horizons in Platelet-Activating Factor Research, C M Winslow, M L Lee. John Wiley, New York 1987; 343–346
   Google Scholar
• Martin-Mondiere C, David P, Sigaux N, Leandri J, Loi-Mace D. Action of BN 52021, a specific platelet activating factor (PAF-acether) antagonist, on microporous polyurethane prothesis implanted in the pig. European Society of Surgical Research Annual Meeting, AarhusThe Netherlands, June, 1987
   Google Scholar
• Pirotzky E, Colliez P, Guilmard C, Schaeverbeke J, Mencia-Huerta J M, Braquet P. Protection of cyclosporin-induced nephrotoxicity by BN 52063 in the rat. The Role Platelet Activating Factor in the Immune Response. Paris June 25–26, 1987, 64 (Abst.)
   Google Scholar
• Hwang S-B, Cheah M J, Lee C-SC, Shen T Y. Effect of nonsteroid antiinflammatory drugs on the drugs on the specific binding of platelet factor to membrane preparation of rabbit platelets. Thromb Res. 1984; 34: 519–531
   PubMedGoogle Scholar
• Bussolino F, Camussi G. Effect of prostacyclin and platelet-activating factor induced rabbit platelet aggregation. Prostaglandins 1980; 20: 781–791
   PubMedGoogle Scholar
• Camussi G, Tetta C, Segoloni G, Chiara Deregibus M, Bussolini F. Neutropenia induced by platelet-activating factor (PAF-acether) released from neutrophils: The inhibitor effect of prostacyclin (PGI2). Agents Actions 1981; 11: 550–553
   PubMedGoogle Scholar
• Camussi G, Tetta C, Bussolino F. Inhibitory effects of prostacyclin (PGI2 on neutropenia induced by intravenous injection of platelet-activating factor (PAF) in the rabbit. Prostaglandins 1983; 25: 343–351
   PubMedGoogle Scholar
• Grandel K E, Farr R S, Wanderer A A, Eisenstadt T C, Wasserman S W. Association of platelet-activating factor with primary acquired cold urticaria. N Engl J Med. 1985; 313: 405–409
   PubMed Web of Science ®Google Scholar
• MacIntyre D E, Shaw A M. Phospholipid-induced human platelet activation: Effects of calcium blockers and calcium chelators. Thromb Res. 1983; 31: 833–844
   PubMedGoogle Scholar
• Khan S N, Lane P A, Smith A D. Desaggregation of PAF-acether aggregated platelets by verapamil and TMB-8 with reversal of phosphorylation of 40K and 20 K proteins. Eur J Pharmacol. 1985; 107: 189–198
   PubMedGoogle Scholar
• Keraly C L, Delautier D, Delabassee D, Chignard M, Benveniste J. Inhibition by ticlopidine of PAF-acether-induced in vitro aggregation of rabbit and human platelets. Thromb Res. 1984; 34: 463–471
   PubMedGoogle Scholar
• Kelefiotis D, Lanara E, Lemionas C V, Siafaka A, Marvis M, Demopoulos C A. Inhibition of the in vivo effects of alkyl acetyl glyceryl phosphorylcholine (AGEPC) on mice by digoxin. First International Conference on Platelet Activating Factor and Structurally Related Ether Lipids, Paris, June 26–29, 1983, 57–101, (Abst.)
   Google Scholar
• Shen T Y, Hwang S-B. The chemical and biological properties of PAF agonists, antagonists, and biosynthetic inhibitors. Platelet-Activating Factor and Related Lipid Mediators, F Snyder. Plenum, New York 1987; 66–87
   Google Scholar
• Qayumi A K, Jamieson W RE, Poostizadeh A. Effects of platelet-activating antagonist CV-3988 in preservation of heart and lung for transplantation. Ann Thor Surg. 1991; 52: 1026–1032
   PubMed Web of Science ®Google Scholar
• Qayumi A K, Jamieson W RE, Poostizadeh A, Germann E, Gillespie K D. Comparison of new iron chelating agents in the prevention of ischemidreperfusion injury: A swine model of heart-lung transplantation. J Invest Surg. 1992; 5: 115–127
   PubMedGoogle Scholar
• Qayumi A K, English J, Feeley E JE, Poostizadeh A, Gillespie K, Nash D. A new platelet activating antagonist, CV-6209 in the management of ischemia-reperfusion injury in a swine model of heart-lung transplantation. Cardiovasc Drug, In press
   Google Scholar
• Qayumi A K, English J E, Fradet G, Ansley D M, Pearson B, Nikbakht-Sangari M, Sammartino C. Extended (20 hours) of lung preservation using PAF-antagonist TCV-309 in combination with prostaglandin PGE. J Heart Lung Transplant 1997; 16: 946–955
   PubMed Web of Science ®Google Scholar
• Qayumi A K, Nikbakht-Sangari M, Godin D V, English J C, Horley K J, Keown P A, Lim S P, Ansley D M, Koehle M S. The relationship of ischemia reperfusion injury and the expression of major histocompatibility complex on host lymphocytes. J Thorac Cardiovasc Surg, In press
   Google Scholar